Beiträge
Myeloid-derived suppressor cells in glioma
/in Glioblastoma, International Publications /von 2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-406Dendritic cell-based immunotherapy in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
/in Glioblastoma, International Publications /von 2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-6Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-9Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
/in Glioblastoma, International Publications /von 2013-08-14 / Cancers (Basel) 2013 Aug;5(3):1020-48Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
/in Dendritic Cells, Glioblastoma, International Publications /von 2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-44Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma
/in Dendritic Cells, Endometrial Cancer, International Publications /von 2010-09-01 / Anticancer Res. 2010 Sep;30(9):3709-14Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications /von 2010-04-01 / Pediatr Blood Cancer 2010 Apr;54(4):519-25Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination
/in Glioblastoma, International Publications /von 2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-73
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
- Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma; a single center phase I/II trial
- MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells